ライフサイエンスコーパス: post-transplantation

1 both the adaptive and innate immune systems post transplantation.

2 viral, blood group or third party antibodies post transplantation.

3 ted with significant mortality and morbidity post-transplantation.

4 hort of 172 serum samples collected serially post-transplantation.

5 T, with 90 in complete remission at 3 months post-transplantation.

6 ncreased hemodynamic performance at 20 weeks post-transplantation.

7 in the patient who came to autopsy 16 years post-transplantation.

8 ing and volume gain at baseline and 6 months post-transplantation.

9 versal of neurological disability at 3 years post-transplantation.

10 and at specified intervals through 12 months post-transplantation.

11 ity as a critical property for MDSC survival post-transplantation.

12 enhance Treg-dependent functions, including post-transplantation.

13 e who came to autopsy 18 months and 16 years post-transplantation.

14 als were sacrificed at 24 h, 72 h and 1 week post-transplantation.

15 The patient was discharged on day 18 post-transplantation.

16 d to display a compromised BBB up to 11 days post-transplantation.

17 an grafts formed tumors approximately 1 year post-transplantation.

18 ore slowly than the normal marrow at 4 weeks post-transplantation.

19 lovirus monitoring by PCR through to day 100 post-transplantation.

20 mRNAs, which reached maximal levels 3 to 6 h post-transplantation.

21 e HLA-A, B, DR matching, donor age, and time post-transplantation.

22 .6% vs. 71.5 +/- 1.8%; P = 0.065) at 30 days post-transplantation.

23 r endothelium injury during preservation and post-transplantation.

24 Patients were followed for >/=7 years post-transplantation.

25 sting pre-transplant, expansion and infusion post-transplantation.

26 served after a median follow-up of 5.5 years post-transplantation.

27 tulates pulmonary IRI that occurs clinically post-transplantation.

28 ectomy of the remaining native kidney at d 5 post-transplantation.

29 a median time of 77 months to graft failure post-transplantation.

30 henocopied Id cDKO cardiac fibrosis 4 months post-transplantation.

31 obtained at baseline and 3, 6, and 12 months post-transplantation.

32 could shape the nature of the host response post-transplantation.

33 s, and complete drug withdrawal by 24 months post-transplantation.

34 cell subset was depleted at all time-points post-transplantation.

35 ial or surgical biopsies and 6 at autopsy or post-transplantation.

36 test transplant recipients for alloantibody post-transplantation?

37 ecovered significant cognitive function from post-transplantation (80 days) to 5 years in all tests (

38 Post-transplantation, a combination of granulocyte colon

39 thresholds with overall mortality by 1 year post-transplantation, adjusting for the use of pre-empti

40 or bronchial hypoxia as a driving factor for post-transplantation airway complications.

41 entified renal miR-182 as the main driver of post-transplantation AKI.

42 0.63, p < 0.0001; CPV: r = 0.43, p = 0.004) post-transplantation along with AT(2)R mRNA in the donor

43 increase significantly at early time points post-transplantation and are detectable by PCR analysis

44 eduction was particularly apparent at 4 week post-transplantation and is independent of CsA immunosup

45 experienced disease progression at 115 days post-transplantation and responded to donor lymphocyte i

46 fit was calculated as the difference between post-transplantation and waitlist life expectancy.

47 ncided with post-ischemic injury over 2 days post-transplantation and was localized by in situ hybrid

48 imerism (median time of first dose, 9 months post-transplantation) and to 24 patients for relapse.

49 diagnosed with CLAD at a median of 95 weeks post-transplantation, and 79 (32%) had 114 episodes of R

50 domonas aeruginosa, are generally manageable post-transplantation, and are associated with favourable

51 ve advanced leukemia, receive growth factors post-transplantation, and have undergone transplantation

52 detect AR in blood independent of age, time post-transplantation, and sample source without addition

53 patients, who came to autopsy 9 and 12 years post-transplantation, and two patients with Parkinson's

54 the severity of hepatitis C virus recurrence post-transplantation are discussed.

55 of autologous anti-multiple myeloma immunity post-transplantation are modalities being tested to enha

56 at day +7 (P = .01) and day +14 (P = .00003) post-transplantation as well as with the allograft CD34(

57 Five patients (12%) remain alive post-transplantation at >or= 63, >or= 71, >or= 86, >or=

58 Transplanted lungs were evaluated at 6 d post-transplantation based on pulmonary function, histol

59 can contribute to biliary remodeling (e.g., post-transplantation) by functional deregulation of the

60 significant therapeutic potential to prevent post-transplantation cancer in immunosuppressed patients

61 component in the progression of CsA-induced post-transplantation cancer.

62 The patients received the usual post-transplantation care given at the institution.

63 Post-transplantation, CD146(+) and CD166(+) progenitors

64 Pretransplantation and post-transplantation clinical variables and data from a

65 AT(2)R mRNA in the donor hearts at one-year post-transplantation (CMIT: r = 0.3, p < 0.0001; CPV: r

66 Key efficacy end points were post-transplantation complete plus near-complete respons

67 oliferative disorder (PTLD) is a devastating post-transplantation complication often associated with

68 A post-transplantation conditioning regimen of total lymph

69 al implications, the effect of DCD livers on post-transplantation costs has not been studied.

70 Furthermore, DCD post-transplantation costs were 30% higher than DBD cost

71 One-year, post-transplantation costs were higher for DCD recipient

72 We sought to compare the post-transplantation course of patients with AATD and AA

73 Post-transplantation CR+nCR rate was significantly highe

74 ietic cell transplantation (Haplo-HCT) using post-transplantation cyclophosphamide (PT-Cy) is increas

75 t disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been d

76 on performed using T-cell-replete grafts and post-transplantation cyclophosphamide achieves outcomes

77 NMA haplo-BMT with post-transplantation cyclophosphamide has encouraging sa

78 lete grafts from haploidentical donors using post-transplantation cyclophosphamide may represent a so

79 transplantation conditioning and high dose, post-transplantation cyclophosphamide to prevent graft r

80 Conclusion Post-transplantation cyclophosphamide-based HAPLO transp

81 patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentic

82 NMA, T-cell-replete haplo-BMT with high-dose post-transplantation cyclophosphamide.

83 50 perfusion units) at a much earlier period post-transplantation (day 4) compared to animals that re

84 axis was solely with PTCy at 50 mg/kg/day on post-transplantation days +3 and +4.

85 iated with increased risk of early (day 0-60 post-transplantation) death (adjusted hazard ratio [HR]

86 ess than 6.5 ng/mL during the first 2 months post-transplantation demonstrated a significantly higher

87 He was vaccinated 4 years post-transplantation, despite diagnosis of a new low-gra

88 ers of patients entered on the waiting list, post-transplantation, died waiting, and currently waitin

89 ion R did not affect stem-cell mobilization, post-transplantation early complications, duration of ho

90 ovirus (CMV) continues to be a major problem post-transplantation; early markers for predicting patie

91 remissions for the majority of patients with post-transplantation Epstein-Barr virus-related lymphoma

92 antation, this decreased markedly by 4 weeks post-transplantation even in the absence of CsA immunosu

93 However, it is not known how specific post-transplantation events (acute or chronic graft-vers

94 amine the relationship between ethnicity and post-transplantation events and determine their net effe

95 Our model demonstrates that common post-transplantation events drive movement from one post

96 splantation quantitative thallium uptake and post-transplantation extent and the histological distrib

97 Pre- and post-transplantation factors can assist in identifying p

98 tween January 2005 and December 2009 and had post-transplantation FDG positron emission tomography/co

99 who received a transplant survive (75%) with post-transplantation follow-up as long as 13 years.

100 psies obtained during the first three months post-transplantation from 172 patients (median follow-up

101 oinfection and the severity of liver disease post-transplantation, graft, or patient survival.

102 c fibrosis-related arthropathy increased the post-transplantation hazard of death.

103 well-tolerated interferon-free treatment for post-transplantation HCV infection.

104 ined with ribavirin for 24 weeks in treating post-transplantation HCV infection.

105 After 7 to 65 days post-transplantation, hearts were harvested and processe

106 A rise in post-transplantation hemoglobin was a significant factor

107 onsumption of camel-derived food products to post-transplantation hepatitis E, which, if detected at

108 ene silencing techniques in the treatment of post-transplantation host rejection is not long lasting

109 By 3 days post-transplantation, however, there were no longer any

110 context of suppressed cell-mediated immunity post-transplantation, humoral immunity has a role in red

111 Obesity was a risk factor for post-transplantation hypertension, dyslipidemia, and dia

112 BM-derived Tns and pDCs favorably regulated post-transplantation immunity in allogeneic hematopoieti

113 of rapamycin (mTOR) inhibitor rapamycin as a post-transplantation immunosuppressive significantly red

114 Six patients received post-transplantation immunosuppressive therapy with meth

115 27(-) B cells were increased through 5 years post-transplantation in both tolerant and nontolerant re

116 Post-transplantation infection causes high mortality and

117 .5 years; 67% male; at a median of 2.0 years post-transplantation, (interquartile range 1.3-3.3 years

118 lated as the difference between waitlist and post-transplantation life expectancy.

119 ber of diseases including liver ischemia and post-transplantation liver failure.

120 PURPOSE Adult post-transplantation lymphoproliferative disease (PTLD)

121 Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disease (PTLD)

122 Post-transplantation lymphoproliferative disease (PTLD)

123 vere life-threatening infections and trigger post-transplantation lymphoproliferative disease (PTLD).

124 ugh TRAFs in tumor tissue from patients with post-transplantation lymphoproliferative disease and non

125 Tumors from six of the patients with post-transplantation lymphoproliferative disease were po

126 Tumors from eight patients with post-transplantation lymphoproliferative disease, two pa

127 ce, risk factors, treatment, and outcomes of post-transplantation lymphoproliferative disorder (PTLD)

128 Post-transplantation lymphoproliferative disorder (PTLD)

129 Post-transplantation lymphoproliferative disorder (PTLD)

130 To further elucidate the role of del-LMP1 in post-transplantation lymphoproliferative disorders (PT-L

131 actors for overall survival in patients with post-transplantation lymphoproliferative disorders (PTLD

132 Post-transplantation management was provided in accordan

133 transgene expression between 14 and 28 days post-transplantation, many of these changes began to nor

134 Post-transplantation mean left ventricular ejection frac

135 At six months post-transplantation, mean serum creatinine was 2.0 +/-

136 Remarkably, 9 days post-transplantation, mice receiving scWAT from exercise

137 </= 44.0 mm Hg had significant increases in post-transplantation mortality (hazard ratio = 1.58; 95%

138 improved, with a dramatic reduction in early post-transplantation mortality and excellent 5-year surv

139 The 30-day post-transplantation mortality rate was 67% for patients

140 Models of 90-day and 1-year post-transplantation mortality were developed using reci

141 els provide a means of assessing the risk of post-transplantation mortality, giving clinicians import

142 ncreasing age was associated with increasing post-transplantation mortality.

143 exception points) due to their high pre- and post-transplantation mortality.

144 </= 44.0 mm Hg was associated with increased post-transplantation mortality.

145 ith hepatocellular carcinoma poorly estimate post-transplantation mortality.

146 plantation are also at higher risk for early post-transplantation mortality.

147 itopes in Goodpasture's disease and Alport's post-transplantation nephritis with the intention of fin

148 In contrast, in patients with Alport's post-transplantation nephritis, alloantibodies bound to

149 Alport's post-transplantation nephritis, which is mediated by all

150 sture's disease and 2 patients with Alport's post-transplantation nephritis.

151 Moreover, post-transplantation non-cell-autonomous mechanisms rest

152 pients and the effect of age on waitlist and post-transplantation outcomes and on transplant-related

153 This study sought to investigate post-transplantation outcomes as a function of race and

154 effects of room-air oxygenation on pre- and post-transplantation outcomes of patients with HPS.

155 rushed transplantation to achieve desirable post-transplantation outcomes.

156 pse free but full donor chimeras at 9 months post-transplantation (P = .0071).

157 in group 2 at 1 year (91%), and 5 year (87%) post-transplantation (P = 0.0019).

158 Cohort B included post-transplantation patients who had either no cirrhosi

159 safe and effective for the growing number of post-transplantation patients who may be candidates for

160 The nephrotic syndrome in early post-transplantation period should prompt a work-up for

161 treated animals was reduced in the immediate post-transplantation period, but by day 100 was increase

162 result in beta cell destruction in the early post-transplantation period.

163 within the graft and persist throughout the post-transplantation period.

164 (56 v 50 years; P < .001), and had delays in post-transplantation platelets recovery (39 v 27 days; P

165 eceptors from perioperation through one-year post-transplantation predict the transplant coronary art

166 s indicate that OECs survive longer than FBs post-transplantation, preserve axons and neurons, and re

167 Post-transplantation progression of neurologic dysfuncti

168 phocytes and in the donor hearts at one-year post-transplantation proved to be multivariate predictor

169 with several aspects of modern management of post-transplantation PTLD.

170 ion do not meet criteria for a more specific post-transplantation pulmonary syndrome.

171 Numerous idiopathic post-transplantation pulmonary syndromes have been descr

172 with aspartate aminotransferase (AST) 14-day post-transplantation (q < 0.05) and were more abundant i

173 f grafted NPCs were found to survive at 24 h post-transplantation, regardless of injury status of the

174 come is largely due to a higher incidence of post-transplantation relapse (20% to 30%).

175 re collected from eight patients with severe post-transplantation reperfusion edema.

176 ftment is assessed 4-6 weeks and 10-12 weeks post-transplantation, respectively, with preparation and

177 er doses of opioid medications were the only post-transplantation risk factor for delirium onset (haz

178 t and prior pain, and higher BUN levels were post-transplantation risk factors for greater delirium s

179 dds of neutropenia after the first or second post-transplantation rituximab increased three-fold with

180 wever, neutropenia after the first or second post-transplantation rituximab treatment occurred in 52%

181 h B-cell non-Hodgkin's lymphoma who received post-transplantation rituximab.

182 genotype other than 1a, and 5 persons had no post-transplantation serum specimens available.

183 Post-transplantation serum specimens were unavailable fo

184 nly used to guide pre-emptive therapy in the post-transplantation setting, few data are available cor

185 Analysis at 75 d post-transplantation showed 2 of the 6 clones engrafting

186 on of liver sections of mice up to 16 months post-transplantation showed no evidence of liver damage.

187 ansplantation events drive movement from one post-transplantation state to another and influence outc

188 Six months post-transplantation, subjects without de novo donor-spe

189 three periods: survival to transplantation, post-transplantation survival and overall survival (i.e.

190 it substantially because age diminishes both post-transplantation survival and waitlist survival appr

191 acteria, especially Mycobacterium abscessus, post-transplantation survival has not been definitively

192 Post-transplantation survival improved annually.

193 Post-transplantation survival in AL has improved, with a

194 might enable clinicians to accurately assess post-transplantation survival in patients with hepatocel

195 Identifying characteristics that affect post-transplantation survival may improve patient select

196 We modeled the post-transplantation survival of adult, first-time liver

197 (88.4%), 3-year (80.3%), and 5-year (74.0%) post-transplantation survival of all other transplant re

198 The post-transplantation survival of patients with hemochrom

199 During 1990-1996, the post-transplantation survival of patients with hemochrom

200 We identified thresholds associated with post-transplantation survival using cubic spline analysi

201 Post-transplantation survival was 95 +/- 4% at three yea

202 Rates of 3-year unadjusted post-transplantation survival were 84% for patients with

203 xamined the consequences of donor smoking on post-transplantation survival, and the potential effect

204 (86.1%), 3-year (80.8%), and 5-year (77.3%) post-transplantation survival, which was not different f

205 ncreased waiting-list survival but decreased post-transplantation survival.

206 that patients with hemochromatosis have poor post-transplantation survival.

207 other causes of liver disease with regard to post-transplantation survival.

208 t affect waiting-list survival but decreased post-transplantation survival.

209 ppraise carefully the high risk of decreased post-transplantation survival.

210 models to identify variables that influence post-transplantation survival.

211 d Cox proportional hazards analysis to model post-transplantation survival.

212 chronic lung allograft dysfunction and worse post-transplantation survival.

213 ransplantation mortality and similar rate of post-transplantation survival.

214 tation, at least in the acute phase (12 days post-transplantation), surviving xenografts were detecte

215 ciated with worse patient and graft survival post-transplantation than other liver diseases.

216 By 6 months post-transplantation, the reconstituted mice had develop

217 reactive astrocytes and microglia at 1 week post-transplantation, this decreased markedly by 4 weeks

218 f immunosuppressive drugs are routinely used post-transplantation to prevent rejection and/or other c

219 iac neural tube and neural crest at 12 hours post-transplantation to the midbrain, but was subsequent

220 CsA-induced VEGF overexpression in terms of post-transplantation tumor development, we injected CT26

221 thful recapitulation of tissue-specific fate post-transplantation underscores the functional potentia

222 to transplantation, and have no prospect for post-transplantation use.

223 f HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of a

224 If post-transplantation variables that were highly correlat

225 and reached a clinically relevant difference post-transplantation versus baseline.

226 Of these 43 patients, 30 (70%) had a post-transplantation virologic response at 12 weeks, 10

227 ts given sofosbuvir and ribavirin, 49% had a post-transplantation virologic response.

228 Increased mortality at 3-months post-transplantation was associated with acute liver fai

229 During immune reconstitution post-transplantation we observed significant though tran

230 al to transplantation, and survival one year post-transplantation were similar to patients without se

231 sed 6-fold in xenograft recipients at day 21 post-transplantation when compared with naive animals.

232 ed near complete BBB reconstitution at day 5 post-transplantation, whereas animals that received sali